Colonia Delicias, Mexico
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Phase
3Span
60 weeksSponsor
Arthrosi TherapeuticsHonolulu, Hawaii
Recruiting
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
Phase
1/2Span
45 weeksSponsor
BioNTech SEHonolulu, Hawaii
Recruiting
Healthy Volunteers
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
The purpose of this study is to investigate the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin, in reducing the risk of the composite of > 50% decline in eGFR, kidney failure, or CV death, in individuals with CKD and HTN. This study consists of a 4-week dapagliflozin Run-in Period for participants untreated with SGLT2i at screening, and a double-blinded period where participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin. Site visits will take place at 2-, 4-, 8-, 16-, 34, and 52-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of primary endpoint events is predicted to have occurred ie, the PACD. All randomised participants including any participants who have prematurely discontinued study intervention will be scheduled for a SCV within a few weeks of the PACD. This period can be extended by the Sponsor. In case of premature discontinuation of blinded study intervention, participants will continue in the study and receive dapagliflozin 10 mg, unless the participant meets dapagliflozin specific discontinuation criteria. If study intervention is temporarily or permanently discontinued, the participant should remain in the study, and it is important that the scheduled study visits (including the PTDV for participants with permanent discontinuation of study intervention) and data collection continue according to the study protocol until the SCV.
Phase
3Span
268 weeksSponsor
AstraZenecaHonolulu, Hawaii
Recruiting
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
Phase
2Span
58 weeksSponsor
PfizerHonolulu, Hawaii
Recruiting
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Phase
2Span
119 weeksSponsor
Eli Lilly and CompanyHonolulu, Hawaii
Recruiting
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
Phase
3Span
140 weeksSponsor
ModernaTX, Inc.Honolulu, Hawaii
Recruiting
Healthy Volunteers
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
Part A Healthy Volunteers Part B and Part C (starts after treatment for Part A has completed) Participants with Obesity
Phase
2Span
141 weeksSponsor
Regeneron PharmaceuticalsHonolulu, Hawaii
Recruiting
Healthy Volunteers
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Phase
3Span
251 weeksSponsor
Madrigal Pharmaceuticals, Inc.Honolulu, Hawaii
Recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Phase
3Span
127 weeksSponsor
Eli Lilly and CompanyHonolulu, Hawaii
Recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Phase
3Span
110 weeksSponsor
Eli Lilly and CompanyHonolulu, Hawaii
Recruiting